Skadden represented Allergan (formerly known as Actavis) in securing the dismissal of federal and state antitrust claims brought by a proposed class of indirect purchasers of the diabetes drugs ACTOS and ACTOplus met. The case was brought against one branded and four generic drug manufacturers, alleging that they conspired to control and delay competition in the market for ACTOS and ACTOplus met. On September 22, Judge Ronnie Abrams of the U.S. District Court for the Southern District of New York dismissed all the claims against Allergan and the other defendants with prejudice.

BACK TO TOP